首页 | 本学科首页   官方微博 | 高级检索  
检索        

2007年我院门诊口服抗糖尿病药应用分析
引用本文:朱莉,孙伟伟,于馨,于国英.2007年我院门诊口服抗糖尿病药应用分析[J].中国医院用药评价与分析,2008,8(5):339-340.
作者姓名:朱莉  孙伟伟  于馨  于国英
作者单位:青岛大学医学院附属医院,青岛市,266003
摘    要:目的:对我院门诊口服抗糖尿病药的应用情况进行分析评估,为临床合理用药提供参考依据。方法:对我院2007年口服抗糖尿病药的用药频度(DDDs)进行统计、分析。结果:葡萄糖苷酶抑制剂药物用药频度较高,占28.39%,其次是磺酰脲类,占25.45%。结论:葡萄糖苷酶抑制剂是新型口服抗糖尿病药,用于降低餐后血糖,其降糖效果显著、安全,是目前糖尿病患者的首选药物。

关 键 词:口服抗糖尿病药  用药频度  糖尿病

Analysis of Outpatient Use of Hypoglycemic Agents in Our Hospital in 2007
ZHU Li,SUN Wei-wei,YU Xin,YU Guo-ying.Analysis of Outpatient Use of Hypoglycemic Agents in Our Hospital in 2007[J].Evaluation and Analysis of Drug-Use in Hospital of China,2008,8(5):339-340.
Authors:ZHU Li  SUN Wei-wei  YU Xin  YU Guo-ying
Institution:(The Affiliated Hospital of Medical College of Qingdao University, Qingdao 266003, China)
Abstract:OBJECTIVE: To evaluate the outpatient use of hypoglycemic agents in our hospital for reference of clinical rational use of this kind of drugs. METHODS: The DDDs of the oral hypoglycenic agents in our hospital in 2007 were analyzed statistically. RESULTS: Leading the list of DDDs was glucosidase inhibitor, which accounted for 28.39% of the total, followed by sulfonylureas which accounted for 25.45 % . CONCLUSION: The glucosidase inhibitor, a new type oral hypoglycemic agent used for lowering postprandial blood sugar level showed remarkable efficacy and safety, so it is currently the first choice for patients with diabetes.
Keywords:Oral hypoglycemic agents  Defined daily dose (DDDs)  Diabetes
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号